Anti-KRAS-G12D T cell receptors

Disclosed is an isolated or purified T cell receptor (TCR) having antigenic specificity for mutated Kirsten rat sarcoma viral oncogene homolog (KRAS) presented in the context of an HLA-Cw*0802 molecule. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal..

Medienart:

Patent

Erscheinungsjahr:

2024

Erschienen:

2024

Enthalten in:

Europäisches Patentamt - (2024) vom: 13. Feb. Zur Gesamtaufnahme - year:2024

Sprache:

Englisch

Beteiligte Personen:

TRAN ERIC [VerfasserIn]
LU YONG-CHEN [VerfasserIn]
PASETTO ANNA [VerfasserIn]
ROBBINS PAUL F [VerfasserIn]
ROSENBERG STEVEN A [VerfasserIn]
ZHENG ZHILI [VerfasserIn]

Links:

Volltext [kostenfrei]

Themen:

Sonstige Themen:
615
A61K: Preparations for medical, dental, or toilet purpose (...)
A61P: Specific therapeutic activity of chemical compounds (...)
bio
C07K: Peptides (peptides containing β-lactam rings c07d; (...)
C12N: Microorganisms or enzymes; compositions thereof; pr (...)
che
G01N: Investigating or analysing materials by determining (...)
tec

Anmerkungen:

Source: www.epo.org (no modifications made), First posted: 2024-02-13, Last update posted on www.tib.eu: 2024-03-06, Last updated: 2024-03-08

Patentnummer:

US11897933

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

EPA01924231X